Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL
October 18th 2024This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.
Read More
FDA Approves Sodium Oxybate to Treat Cataplexy or EDS in Pediatric Patients With Narcolepsy
Published: October 17th 2024 | Updated: October 17th 2024Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.
Read More
Removing Mesna From Cyclophosphamide Cycles in VAdriaC-IE for Ewing Sarcoma
This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.
Read More
FDA Approves Foscarbidopa/Foslevodopa for Motor Fluctuations in Adults With Parkinson Disease
Published: October 17th 2024 | Updated: October 17th 2024This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.
Read More
Humanizing Pharmacy: Shifting From Volume to Value for Improved Care and Reduced Pharmacist Burnout
October 17th 2024Retail pharmacies benefit from the shift from a volume-centric model to a value-centric approach that focuses on enhancing patient care, reducing pharmacist burnout, and leveraging technology to improve efficiency and expand the scope of pharmacy services.
Read More